Skip to main content
. 2020 Jun 15;201(12):1488–1498. doi: 10.1164/rccm.201906-1215OC

Figure 4.

Figure 4.

(A and B) Difference in the levels of urinary LTE4 (A) and tetranor-PGDM (B) concentrations between the placebo and omalizumab phases. Wilcoxon signed-rank test; *P < 0.05. Circles (placebo phase) and squares (omalizumab phase) indicate median values, and bars indicate interquartile ranges. LTE4 = leukotriene E4; tetranor-PGDM = 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid.